Compare Hormel Foods Corp (HRL) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Invesco Ltd. — how do they compare? Hormel Foods Corp trades at $24.3 (market cap $13.37B), while Invesco Ltd. trades at $31.45 (market cap $13.85B). The key difference: Hormel Foods Corp and Invesco Ltd. are close in size by market cap, and Hormel Foods Corp pays the higher dividend (4.81%). Which is the better fit depends on your goals.
| HRL | IVZ | |
|---|---|---|
Market Cap | $13.37B | $13.85B |
Sector | Consumer Staples | Financials |
52-Week High | $29.25 | $32.01 |
52-Week Low | $19.74 | $20.67 |
Enterprise Value | $15.37B | $24.01B |
Dividend Yield | 4.81% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $24.41, down 1.21% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 28.6x and modest 3.8% net margin, while revenue has been stable around $12B annually. Recent corporate developments include the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic refocusing.
HRL offers defensive appeal with consistent dividends and a 4.6% yield, but faces margin pressure and modest growth prospects. Analyst consensus is Hold with a $26.33 price target, suggesting limited upside. Key risks include consumer spending sensitivity and execution challenges under new leadership.
Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.
The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
